Paroxysmal nocturnal hemoglobinuria (PNH) , a rare acquired blood disorder, is caused by a genetic mutation of the X-linked gene phosphatidylinositol glycan class A (PIGA) which reduces or even removes glycosylphosphatidylinositol (GPI)-anchored proteins (complement inhibitors CD55 and CD59) on hematopoietic stem cells. Consequently, patients are prone to intravascular hemolysis, thrombosis, cytopenia, organ dysfunction, and hypocellular or dysplastic bone marrow. Here is a case report of a patient whose PNH diagnosis was established after she received the mRNA COVID-19 vaccine, which revealed the underlying hematologic disorder.
The case A previously healthy 29-year-old female presented to the clinic for evaluation of fatigue and shortness of breath in the setting of new-onset pancytopenia . Six months before , she suffered a mild COVID-19 infection, from which she recovered via home…
